fda warning letters compounded semaglutide november 2025 US sends 25 to telehealth companies over claims on weight-loss drugs FDA Warns Novo Nordisk on

References 1.Gulewitsch W

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases

Absorption and circular dichroism spectra of individual proteins from Escherichia coli ribosomes

In scientific updates, a new study (GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy) suggests that taking a GLP-1 may be associated with an increased risk of developing NAION, a type of eye stroke that can cause sudden, permanent blindness

The FDA hasn't approved it as safe or effective

These findings suggest BPC-157 may modulate neuroinflammation and promote neural tissue preservation through mechanisms consistent with its known cytoprotective activity in other tissue types